Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT737 in Relapsed/Refractory Acute Myeloid Leukemia
NCT07676006Phase 1Not yet recruiting
- Sponsor
- Grit Biotechnology
- Start
- May 2027
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SLATEv1 in acute myeloid leukemia (AML), sponsored by Grit Biotechnology. Primary endpoints: Proportion of participants experiencing dose limiting toxicity at 28 days, Adverse Events occurring after infusion and their proportions at 28 days and 2 more. Planned start May 2027; status: not yet recruiting.
02
Drugs
SLATEv1
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07676006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07676006.